Special Notice
Last updated Wednesday, 04 February 2009

The following information is being provided by the International Society for Magnetic Resonance in Medicine (ISMRM) as a courtesy to the MR community.  If you have additional articles or publications regarding this which you feel would be of interest and assistance, please send the citations to the ISMRM, and we will add these resources to this page.  Send them to the attention of Roberta A. Kravitz, ISMRM Executive Director, at roberta@ismrm.org.
Disclaimer:  Please note the ISMRM provides this website as a public service. Users of this website are responsible for checking the accuracy, completeness, content, currency, suitability, and timeliness of all information. The ISMRM makes no representations, guarantees, or warranties, expressed or implied, as to the accuracy, completeness, content, currency, suitability, and timeliness of the information provided via this website. This information is provided on an "as is" basis. The ISMRM reserves the right to add, remove or edit any materials from its official web site without notice.

The ISMRM specifically disclaims any and all liability for any claims or damages that may result from providing the website or the information it contains, including any websites maintained by third parties and linked to or from the ISMRM website. The ISMRM makes no effort to independently verify, and does not exert editorial control over, information or services provided on pages outside the ismrm.org domain.

 Special Symposium on  NSF/NSD from the Joint Annual Meeting ISMRM-ESMRMB 2007 available online

The FDA (United States Food & Drug Administration) has received additional information about a new disease, known as Nephrogenic Systemic Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF/NFD), which may occur in patients with moderate to end-stage kidney disease after they have had a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) scan with a gadolinium-based contrast agent.

The FDA has released the following:

In addition, the EMEA (European Agency for the Evaluation of Medicinal Products) has released the following information:

Additional resources:

The Radiological Society of North America (RSNA) has made two articles available free of charge on the Radiology Web site:
  • New information on the link between gadolinium-based contrast agents and the rare disease nephrogenic systemic fibrosis is available in the RSNA peer-reviewed journal RADIOLOGY. “Nephrogenic Systemic Fibrosis: Risk Factors and Incidence Estimation,” by Elizabeth A. Sadowski, M.D., and colleagues will appear in the April print issue and is available now online at http://radiology.rsnajnls.org/cgi/content/full/2431062144v1.
  • An editorial, “Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis,” by Phillip H. Kuo, M.D., Ph.D., and colleagues is available in the March print issue or online at http://radiology.rsnajnls.org/cgi/content/full/2423061640v1.

In addition, the February issue of RSNA News includes an article on this topic at http://www.rsna.org/Publications/rsnanews/feb07/upload/RSNANews_Feb07_Gadolinium.pdf

  • NSF Registry - Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2007
  • Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?  T. Grobner; Oxford University Press on behalf of ERA-EDTA, Nephrol Dial Transplant 2006; 21:1104–1108 and Response to letter to the Editor, Nephrol Dial Transplant 2006; 21:3604-5
  • Nephrogenic Systemic Fibrosis:  Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging, P. Marckmann, L. Skov, K. Rossen, A. Dupont, M. Damholt, J. Heaf, and H. Thomsen; American Society of Nephrology, 2006; JAmSocNephrol17:2359–2362,2006.doi:10.1681/ASN.2006060601
  • Editorial:  Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?  H. Thomsen, S.K. Morcos, and P. Dawson; Clinical Radiology (2006) 905-906
  • Gadolinium deposition in nephrogenic fibrosing dermopathy, A. Boyd, J. Zic, and J. Abraham; J Am Acad Dermatol, Articles in press, 2007 American Academy of Dermatology, Inc.
  • Letter to the Editors:  Gadolinium and nephrogenic fibrosing demopathy in pediatric patients, V. Dharnidharka, S. Wesson, and R. Fennell; Pediatric Nephrology, DOI 10.1007/s00467-006-0384-z (Springer)